Synergy to start Phase II study of constipation drug

Synergy Pharmaceuticals (SGYP) has unveiled plans to start a Phase II trial of SP-333, the company's proprietary next-generation guanylate cyclase-C (GC-C) agonist, for the treatment of opioid-induced constipation (OIC).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news